• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Humanigen, Inc. (Amendment)

    6/8/21 8:05:38 PM ET
    $HGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HGEN alert in real time by email
    SC 13D/A 1 nomisbay-sc13da_052821.htm AMENDMENT TO FORM SC 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D/A

    (RULE 13D – 101)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a)

     

    (Amendment No. 6)*

     

    HUMANIGEN, INC.

    (Name of Issuer)

     

    COMMON STOCK, PAR VALUE $.001 per share

    (Title of Class of Securities)

    444863 10 4

    (CUSIP Number)

    Nomis Bay LTD

    Wessex House, 3rd Floor, 45 Reid Street

    Hamilton, Bermuda, HM 12

    441-279-2088

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    05-28-2021

    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this Schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    Note: Schedules filed in paper format shall include a signed original and five copies of the Schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (‘Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     CUSIP No. 444863 10 4    

     

    1

    name of reporting persons
    i.r.s. identification nos. of above persons

    Nomis Bay LTD

     
    2

    check the appropriate box if a member of a group*

     

    (a) ☐
    (b) ☐
    3

    sec use only

     

     
    4

    source of funds*

    WC

     
    5

    check box if disclosure of legal proceedings is required pursuant to items 2(d) or 2(e)

     

    ☐
    6

    citizenship or place of organization

    Bermuda

     
    number of
    shares
    beneficially
    owned by
    each
    reporting
    person
    with
      7

    sole voting power

    4,023,975

     
    8

    shared voting power

    0

     
    9

    sole dispositive power

    4,023,975

     
    10

    shared dispositive power

    0

     
    11

    aggregate amount beneficially owned by each reporting person

    4,023,975

     
    12

    check box if the aggregate amount in row (11) excludes certain shares*

     

    ☐
    13

    percent of class represented by amount in row (11)

     

    6.81% (1)

     
    14

    type of reporting person*

     

    OO

     

    * SEE INSTRUCTIONS

    (1) Based upon 59,083,706 shares of Common Stock outstanding as of May 5, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q, filed with the U.S. Securities and Exchange Commission on May 13, 2021.

     

     

    This Amendment No. 6 to Schedule 13D (this “Amendment No. 6”) amends and supplements the statement on Schedule 13D of Nomis Bay LTD (the “Reporting Person”) filed on July 13, 2016 (the “Original Schedule 13D”) with the Securities and Exchange Commission (the “SEC”); Amendment No. 1 to the Original Schedule 13D filed on February 1, 2018 (“Amendment No. 1”) with the SEC; Amendment No. 2 to the Original Schedule 13D filed on February 1, 2018 (“Amendment No.2”) with the SEC; Amendment No. 3 to the Original Schedule 13D filed on July 21, 2020 (“Amendment No. 3”) with the SEC; Amendment No. 4 to the Original Schedule 13D filed on March 25, 2021 (“Amendment No.4”) with the SEC; Amendment No. 5 to the Original Schedule 13D filed on May 27, 2021 (“Amendment No.5”) with the SEC and as amended hereby, the “Schedule 13D”. This filing of Amendment No. 6 relates to the Reporting Person’s beneficial ownership of the Shares (herein defined) of the Issuer (herein defined). Except as expressly amended or supplemented in this Amendment No. 6, all other information is the Schedule 13D is as set forth therein. Only the Items amended are set forth herein. Unless otherwise defined, all capitalized terms used herein shall have the respective meanings given such terms in the Schedule 13D.

     

    This Amendment No. 6 reflects various sales of the Shares (as more particularly described below) by the Reporting Person, and the corresponding change in beneficial ownership of Shares by the Reporting Person.

     

    Item 1. Security and Issuer.

     

    Item 1 is hereby amended and restated in its entirety as follows:

     

    This statement relates to the Common Stock, par value $0.001 (the “Shares”), of Humanigen, Inc., a Delaware corporation (the “Issuer”). The address of the principal executive offices of the Issuer is 533 Airport Boulevard, Suite 400, Burlingame CA 94010.

     

    Item 4. Purpose of Transaction.

     

    Item 4 of the Schedule 13D is hereby amended and supplemented by the incorporation by reference of the information provided below in the response to Item 5.

     

     

     

    Item 5. Interest in Securities of the Issuer.

     

    Item 5 is hereby amended and restated as follows:

     

      (a) See rows (11) and (13) of the cover page to this Amendment No. 6 for the aggregate number of shares of Common Stock and the percentage of the Common Stock beneficially owned by the Reporting Person.

     

      (b) See rows (7) through (10) of the cover page to this Amendment No. 6 for the number of shares of Common Stock as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.

     

      (c) From March 29, 2021 through May 27, 2021, the Reporting Persons disposed of 976,025 shares of Common Stock in a series of transactions. Details by date are provided below.

    Number of shares of Common

    Stock

      Date  

    Price Per Share

    Consideration1

      Type of Transaction
    25,000   04/30/2021   19.031   Open Market Sale
    100,000   05/03/2021   19.260   Other2
    2,017   05/03/2021   19.307   Open Market Sale
    48,449   05/05/2021   19.540   Open Market Sale
    50,000   05/07/2021   19.166   Open Market Sale
    2,430   05/10/2021   19.000   Open Market Sale
    18,739   05/11/2021   18.392   Open Market Sale
    10,100   05/12/2021   18.470   Open Market Sale
    25,000   05/13/2021   17.024   Open Market Sale
    55,377   05/14/2021   18.124   Open Market Sale
    7,234   05/14/2021   18.073   Open Market Sale
    25,000   05/17/2021   18.274   Open Market Sale
    42,197   05/18/2021   18.274   Open Market Sale
    35,000   05/20/2021   19.542   Open Market Sale
    79,800   05/21/2021   20.839   Open Market Sale
    100,785   05/24/2021   20.078   Open Market Sale
    59,483   05/25/2021   20.262   Open Market Sale
    119,789   05/26/2021   21.421   Open Market Sale
    153,405   05/27/2021   21.951   Open Market Sale
    16,220   05/28/2021   22.803   Open Market Sale

     

    1  A total of approximately $39,024.00 in commissions was also paid in connection with these sales.
    2 The reporting person disposed of the common stock in a private transaction in exchange for services rendered having an estimated market value of $1,926,000

     

      (d) The Reporting Person and its stockholders have the right to participate in the receipt of dividends from, or proceeds from the sale of, the Shares reported herein in accordance with their respective ownership interests in the Reporting Person.

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

     

    Title Price Transaction Date Code Quantity Expiration Date Price
    Call Option (Obligation to sell) $20 05/12/2021 S 500 05/21/2021 $0.1
    Call Option (Obligation to sell) $20 05/20/2021 S 100 05/21/2021 $0.15
    Call Option (Obligation to sell) $22.5 05/21/2021 S 141 05/21/2021 $0.05
    Call Option (Obligation to sell) $20 05/21/2021 S 200 05/21/2021 $0.5

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: June 8, 2021

     

    Nomis Bay LTD

     

    By: /S/  Peter Poole  
    Name: Peter Poole  
    Title: Director  

     

     

     

     

     

     

    Get the next $HGEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HGEN

    DatePrice TargetRatingAnalyst
    7/13/2022$13.00 → $2.00Buy → Neutral
    ROTH Capital
    7/13/2022$30.00 → $2.00Overweight → Neutral
    Cantor Fitzgerald
    7/13/2022Buy → Neutral
    H.C. Wainwright
    9/10/2021$9.00Buy → Hold
    Jefferies
    9/9/2021Outperform → Neutral
    Credit Suisse
    9/9/2021$36.00 → $28.00Buy
    H.C. Wainwright
    9/9/2021Neutral → Underweight
    JP Morgan
    8/13/2021$25.00 → $24.00Outperform
    Credit Suisse
    More analyst ratings

    $HGEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Humanigen - Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel Mechanism of Action for Chronic Myelomonocytic Leukemia (CMML), an Orphan Form of Leukemia

      CMML is an aggressive, poorly understood cancer; approximately 20% of patients survive three years from diagnosisEleven subjects dosed with lenzilumab and with current standard of care, azacitidineSix evaluable subjects, including those with high risk CMML, demonstrated clinical benefit at three months follow-upLenzilumab appears to be well-toleratedShort Hills, New Jersey and Adelaide, South Australia--(Newsfile Corp. - April 14, 2023) - Humanigen, Inc. (NASDAQ:HGEN), Humanigen Australia Pty Ltd, (Humanigen) and the South Australian Health and Medical Research Institute (SAHMRI) today presented (poster CT085/13); the design and baseline results of the Precision Approach to Chronic Myelomono

      4/14/23 12:05:00 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Humanigen Reports Third Quarter 2022 Financial Results

      Short Hills, New Jersey--(Newsfile Corp. - November 14, 2022) - Humanigen, Inc. (NASDAQ:HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today reported financial results for the third quarter and nine months ended September 30, 2022.In July 2022, the company announced a strategic realignment of its pipeline, resources and regulatory strategy. The company is accelerating the development of lenzilumab in chronic myelomonocytic leukemia (CMML), a rare blood cancer, for which the PREACH-M study is already underway. The company is also contin

      11/14/22 4:01:00 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Humanigen Announces Participation and Presentation at Jefferies London Healthcare Conference

      Short Hills, New Jersey--(Newsfile Corp. - November 10, 2022) - Humanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating certain inflammatory and oncological conditions, today announced that Cameron Durrant, MD, MBA, Chairman & CEO, will give a corporate presentation at 11:25am EST (4:25pm local time) at the Jefferies London Healthcare Conference taking place on November 17, 2022. Dr. Durrant will provide an update on the clinical development of lenzilumab, Ifabotuzumab and HGEN005.A livestream will be available and a webcast link to a recording of the event will be posted to the "Events and Presentations" section of Humanige

      11/10/22 8:02:00 AM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Humanigen Inc. (Amendment)

      SC 13G/A - HUMANIGEN, INC (0001293310) (Subject)

      2/1/23 1:21:00 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Humanigen Inc. (Amendment)

      SC 13D/A - HUMANIGEN, INC (0001293310) (Subject)

      3/17/22 4:28:37 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Humanigen Inc. (Amendment)

      SC 13G/A - HUMANIGEN, INC (0001293310) (Subject)

      2/14/22 4:54:04 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HGEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors

      Former Novartis Veteran Brings Deep Expertise in Drug Development and Commercialization CAMBRIDGE, Mass., Sept. 1, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to using mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced the appointment of Rainer Boehm as an independent director to its Board of Directors. Mr. Boehm will serve on Omega's audit and compensation committees. "Rainer's growth-oriented perspective and global strategic management experience will be invaluable to Omega in this next phase o

      9/1/22 7:00:00 AM ET
      $CLLS
      $HGEN
      $OMGA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Aquestive Therapeutics Strengthens Team to Align with Strategic Focus on Allergy Space

      Appoints Timothy E. Morris, a veteran biotech executive with over 35 years of experience in executive and financial leadership, to Board of DirectorsNames Kenneth Truitt, M.D., with over 25 years of clinical and regulatory experience across biotechnology and large pharmaceutical companies, as Chief Medical Officer Reports inducement grant to Dr. Truitt under Nasdaq Listing Rule 5635(c)(4) WARREN, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today the appointments of Timothy E. Mo

      8/10/22 4:50:35 PM ET
      $AQST
      $DBVT
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Humanigen Announces Ken Trbovich Appointed as Senior Vice President, Investor Relations

      BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced the appointment of Ken Trbovich to the newly-created role of SVP of Investor Relations, effective immediately, reporting to Timothy E. Morris, COO/CFO of Humanigen. Mr. Trbovich brings to Humanigen 20 years of experience on Wall Street as a Managing Director and Senior Analyst at several leading investment banks including Janney Montgomery Scott, MLV & Co. (now part of B. Riley), C.E. Unterberg, Towbin (now part of C

      6/7/21 8:00:00 AM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HGEN
    Financials

    Live finance-specific insights

    See more
    • Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate Update

      Humanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced that it will host a conference call and webcast to discuss The Lancet Respiratory Medicine publications and provide a corporate update at 8am EST on December 2, 2021. The peer-reviewed paper in The Lancet Respiratory Medicine is available via the follow link: https://doi.org/10.1016/S2213-2600(21)00494-X The associated comment in The Lancet Respiratory Medicine is available via the following link: https://doi.org/10.1016/S2213-2600(21)00539-7 Details about how to access the conference call and webcast are pr

      12/1/21 6:45:00 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HGEN
    SEC Filings

    See more
    • Humanigen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - HUMANIGEN, INC (0001293310) (Filer)

      1/8/24 5:02:09 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Humanigen Inc.

      25-NSE - HUMANIGEN, INC (0001293310) (Subject)

      10/12/23 8:19:55 AM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Humanigen Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - HUMANIGEN, INC (0001293310) (Filer)

      9/14/23 4:01:46 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Humanigen downgraded by ROTH Capital with a new price target

      ROTH Capital downgraded Humanigen from Buy to Neutral and set a new price target of $2.00 from $13.00 previously

      7/13/22 9:07:33 AM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Humanigen downgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald downgraded Humanigen from Overweight to Neutral and set a new price target of $2.00 from $30.00 previously

      7/13/22 7:40:18 AM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Humanigen downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Humanigen from Buy to Neutral

      7/13/22 7:39:46 AM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chappell Dale sold $4,250 worth of shares (386,350 units at $0.01) (SEC Form 4)

      4 - HUMANIGEN, INC (0001293310) (Issuer)

      10/20/23 6:50:35 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Hohneker John

      4 - HUMANIGEN, INC (0001293310) (Issuer)

      7/29/22 6:31:06 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Buxton Cheryl

      4 - HUMANIGEN, INC (0001293310) (Issuer)

      7/29/22 6:31:07 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care